References
- Sokoloff C, Daoust R, Paquet J, et al. Is adequate pain relief and time to analgesia associated with emergency department length of stay? A retrospective study. BMJ Open. 2014;4(3):e004288.
- Tan M, Law LS, Gan TJ. Optimizing pain management to facilitate enhanced recovery after surgery pathways. Can J Anaesth. 2015;62(2):203–218.
- Chou R, Gordon DB, de Leon-casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131–157.
- Sabri A, Szalas J, Holmes KS, et al. Failed attempts and improvement strategies in peripheral intravenous catheterization. Biomed Mater Eng. 2013;23(1–2):93–108.
- Taddio A, Ipp M, Thivakaran S, et al. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine. 2012;30(32):4807–4812.
- Miner JR, Moore J, Gray RO, et al. Oral versus intravenous opioid dosing for the initial treatment of acute musculoskeletal pain in the emergency department. Acad Emerg Med. 2008;15(12):1234–1240.
- Reisfield GM, Wilson GR. Rational use of sublingual opioids in palliative medicine. J Palliat Med. 2007;10(2):465–475.
- Jove M, Griffin DW, Minkowitz HS, et al. Sufentanil sublingual tablet system for the management of postoperative pain after knee or hip arthroplasty: a randomized, placebo-controlled study. anesthesiology. 2015;123(2):434–443.
- Melson TI, Boyer DL, Minkowitz HS, et al. Sufentanil sublingual tablet system vs. intravenous patient-controlled analgesia with morphine for postoperative pain control: a randomized, active-comparator trial. Pain Pract. 2014;14(8):679–688.
- Miner JR, Melson TI, Leiman D, et al. Pooled Phase III safety analysis of sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain. Pain Manag. 2019;9(3):259–271.
- Miner JR, Rafique Z, Minkowitz HS, et al. Sufentanil sublingual tablet 30mcg for moderate-to-severe acute pain in the ED. Am J Emerg Med. 2018;36(6):954–961.
- Minkowitz HS, Leiman D, Melson T, et al. Sufentanil sublingual tablet 30 mcg for the management of pain following abdominal surgery: a randomized, placebo-controlled, phase-3 study. Pain Pract. 2017;17(7):848–858.
- Rauck RL, Oh DA, Singla N, et al. Pharmacokinetics and safety of fentanyl sublingual spray and fentanyl citrate intravenous: a multiple ascending dose study in opioid-naive healthy volunteers. Curr Med Res Opin. 2017;33(11):1921–1933.
- Rauck RL, Oh DA, Singla N, et al. Pharmacokinetics of fentanyl sublingual spray in opioid-naive participants: results of a phase 1, multiple ascending dose study. Clin Drug Invest. 2018;38(8):715–726.
- Guitart J, Vargas MI, De Sanctis V, et al. Correction to: efficacy and safety of sublingual fentanyl tablets in breakthrough cancer pain management according to cancer stage and background opioid medication. Drugs R D. 2018;18(3):247–248.
- Miner JR, Kletti C, Herold M, et al. Randomized clinical trial of nebulized fentanyl citrate versus i.v. fentanyl citrate in children presenting to the emergency department with acute pain. Acad Emerg Med. 2007;14(10):895–898.
- Fisher DM, Chang P, Wada DR, et al. Pharmacokinetic properties of a sufentanil sublingual tablet intended to treat acute pain. Anesthesiology. 2018;128(5):943–952.
- Vlok R, An GH, Binks M, et al. Sublingual buprenorphine versus intravenous or intramuscular morphine in acute pain: a systematic review and meta-analysis of randomized control trials. Am J Emerg Med. 2019;37(3):381–386.